Introduction
The HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) response to influenza A is dominated by M1 58-66 -specific CD8 ϩ T cells which express V β 17 ϩ TCR (1, 2) . Such TCR dominance may reflect a trimming of the available TCR repertoire against an antigen (2, 3) or might be explained by maturation of the response with selection of a narrow range of high-affinity TCR after repeated antigen exposure (4) (5) (6) . In the preceding paper in this issue we showed that TCR usage during in vitro primary HLA-A*0201-restricted M1 58-66 -specific responses is diverse and TCR V β 17 dominance is acquired following the first exposure to influenza A. This observation suggests that thymic selection is not an over-riding factor in shaping the TCR repertoire selected by influenza A in HLA-A*0201 subjects. Having demonstrated that oligoclonal TCR V β 17 usage in the M1 58-66 -specific CD8 ϩ T cell response is acquired, it becomes important to determine the fate of the 'non-V β 17 ϩ ' M1 58-66 -specific clones identified during the primary in vitro cord blood response. Do they persist, but remain subdominant? Previous studies have failed to identify subdominant M1 58-66 -specific clones in HLA-A*0201 ϩ adult subjects. It is possible that this resulted from the limitations of the in vitro conditions used (1, 2, 7, 8) In this study we removed V β 17 ϩ cells from peripheral blood mononuclear cells (PBMC) prior to in vitro stimulation with influenza A and generated subdominant M1 58-66 -specific clones in all adult individuals studied. The isolation of M1 58-66 -specific clones expressing different TCR enabled a comparison of the functional properties at a clonal level. We compared phenotype, peptide sensitivity, CD8 dependence and HLA-A*0201/M1 58-66 tetramer binding of these CTL clones to allow comparison of the relative avidity of different M1 58-66 -specific clones for cognate antigen. Tetramers are particularly valuable reagents for this type of comparative study as their intensity of binding to and the rate of dissociation from T cells has been used to estimate the affinity and kinetics of the specific TCR-MHC-peptide interaction (6, 9) .
Methods

Generation of V β 17 ϩ and 'non-V β 17 ϩ ' M1 58-66 -specific CTL lines and clones
HLA-A*0201-restricted influenza A/M1 58-66 -specific CTL lines and clones were generated as previously described (2) . Briefly, freshly isolated PBMC from an HLA-A*0201 adult volunteer were depleted of either V β 17 ϩ cells or control V β 22 ϩ cells by immunomagnetic depletion. Depletion was typically Ͼ97%. The PBMC depleted of V β 17 ϩ or V β 22 ϩ cells were infected with 200 HAU of influenza A (AX/31). After 1 h incubation at 37°C, cells were cultured in RPMI-10(AB) [RPMI 1640 (Sigma, St Louis, MO), 10% human AB serum, 2 mM Lglutamine, 1 mM sodium pyruvate and 25 mM HEPES buffer] for 7 days. On day 7 and weekly thereafter, the cells were harvested, counted and replated in 24-well plates at 2ϫ10 6 cells/well in RPMI-10(AB) containing 10 IU/ml IL-2 (Boehringer Mannheim, Mannheim, Germany). Cultures were re-stimulated with irradiated autologous M1 58-66 -pulsed (10 -6 M) PBMC at a responder:stimulator ratio of 1:1. On day 21 cultures were tested for influenza A and M1 58-66 -specificity by 51 Cr-release assay and lines were confirmed to be V β 17 ϩ and 'non-V β 17 ϩ ' respectively by two-colour immunofluorescence analysed by flow cytometry. If M1 58-66 -specificity was not detected from V β 17 depleted samples, the procedure was repeated using a re-stimulation protocol designed to induce 'primary' in vitro peptide-specific CTL responses (11). CTL clones were generated from V β 17 ϩ and 'non-V β 17 ϩ ' CTL lines by limiting dilution as described (2) , and stimulated weekly using irradiated allogeneic PBMC, phytohemagglutinin (1 µg/ml; Sigma), lymphocult-T (1 IU/well; Biotest, Dreieich, Germany), rhIL-2 (20 IU/ml; Boehringer Mannheim) and IL-7 (5 ng/ml; Genzyme, Cambridge, MA). Clones were assayed for M1 58-66 specificity after 21 days.
Cytotoxicity assays
Standard 51 Cr-release assays were performed using 51 Crlabelled HLA-A*0201 ϩ CIRA2 targets (2000/well). Targets were pulsed with various concentrations of M1 58-66 peptide (10 -6 to 10 -13 M) or infected with 200 HAU influenza A (AX/ 31). Control targets included CIRA2 cells in the absence of peptide and CIRA2 cells pulsed with the HLA-A*0201-binding Plasmodium cp36 peptide (36) . For peptide sensitivity assays an E:T ratio of 5:1 was used for each clone. For CD8 blocking experiments, the CTL clones were incubated with varying concentrations of anti-CD8 antibody (OKT8) for 30 min prior to adding the targets. A control isotype-matched CD4 blocking antibody (OKT4) was used in each experiment.
Staining and analysis of CD8 ϩ T cells
Cells were analysed by flow cytometry using the FACScan (Becton Dickinson, La Jolla, CA). Live cells were gated based on FSC/SSC profiles. The TCR V β gene segment usage by the various clones generated was determined by two-colour immunofluorescence using a panel of FITC-conjugated anti-TCR V β mAb (TCR Workshop, San Francisco, 1995) and anti-CD8-phycoerythrin (Becton Dickinson). TCR αβ and CD8 expression levels were determined using FITC-conjugated anti-TCRαβ and phycoerythrin-conjugated anti-CD8 (both from Becton Dickinson). The staining procedure was as previously described (2) .
Tetramer binding
The soluble tetrameric HLA-A*0201/M1 58-66 complex conjugated to streptavidin-TriColor used in this study has previously been described (8) . In brief, cells were incubated for 1 h at 4°C, with soluble tetrameric HLA-A*0201/M1 58-66 complexes conjugated to streptavidin-TriColor (0.5 mg/ml), before washing twice with PBS and fixing in 2% paraformaldehyde. Single-colour fluorescence intensity was measured by flow cytometry using the FACScan (Becton Dickinson).
Cytokine production
CTL clones were incubated with CIRA2 cells (2000/well) which had been pulsed with M1 58-66 peptide (10 -6 M), a control Plasmodium cp36 peptide (10 -6 M) or no peptide at an effector to stimulator ratio of 5:1 for 6 h. IFN-γ, tumour necrosis factor-α (TNF-α) and IL-4 production by the clones was measured in the supernatant using standard ELISA kits (Genzyme). IFN-γ production as a function of the concentration of M1 58-66 peptide used to pulse target cells was also determined.
Results
TCR V β gene segment usage of HLA-A*0201-restricted M1 58-66 peptide-specific clones
CTL clones recognizing M1 58-66 peptide are largely V β 17 ϩ and previous reports have suggested that the HLA-A*0201- Fig. 1 . Cytotoxic activity of M1 58-66 -specific clones expressing different TCR. Influenza A/M1 58-66 -specific clones expressing different TCR produce similar levels of lysis at equivalent E:T ratios in the presence of excess exogenous M1 58-66 peptide and were also able to recognize endogenously processed peptide. 51 Cr-release assays were performed using CIRA2 targets (2000/well) pulsed with M1 58-66 peptide (10 -6 M) or infected with influenza A virus (200 HAU). Lysis of targets in the absence of peptide or pulsed with a control A2-binding Plasmodium cp36 peptide was Ͻ3% for each clone. Assays were performed in triplicate and the SD of the mean is shown in each case.
restricted M1 58-66 -specific CTL response is highly dependent on the V β 17 ϩ population (1, 7, 8) . To investigate whether subdominant, 'non-V β 17 ϩ ' M1 58-66 -specific CTL clones exist, we depleted V β 17 ϩ cells from fresh PBMC prior to in vitro restimulation. 'Non-V β 17 ϩ ' M1 58-66 -specific CTL lines were successfully generated from six of six HLA-A*0201 individuals (Table 1 ). For three of the subjects (MJ, MA and LM), 'non-V β 17 ϩ ' M1 58-66 -specific CTL lines were successfully generated using the 'standard' re-stimulation protocol (10) . However, in the other three subjects (LF, MR and JM), 'non-V β 17 ϩ ' M1 58-66 CTL could only be generated by using a restimulation protocol designed to generate in vitro primary responses (11) ( Table 1) .
The TCR usage of these CTL lines was shown to be heterogeneous and different for each individual (Table 1) . No significant TCR V β expansion was detected for two of the CTL lines (MA and JM). M1 58-66 -specific clones expressing V β 13.6, V β 23 and V β 8.1 were derived from one of these CTL lines (MR). These V β cell populations comprised 1.5, 1 and 4% respectively of the CD8 population of freshly isolated PBMC from this individual. Untreated PBMC from the same individual resulted in a CTL line containing Ͼ90% CD8 ϩ V β 17 ϩ cells and several V β 17 ϩ , but no 'non-V β 17 ϩ ' clones, were generated. Therefore, although V β 17 ϩ CTL dominate the HLA-A*0201-restricted influenza A/M1 58-66 -specific CTL response, subdominant CTL expressing other TCR specific for the same MHC-peptide complex persist and can be expanded in the absence of the dominant V β 17 ϩ CTL population during in vitro culture.
Peptide sensitivity of HLA-A*0201-restricted M1 58-66 -specific CTL clones
Efficiency of target cell lysis by CTL is dependent on the TCR affinity for and the half-life of the interaction of the TCR with the MHC-peptide complex (6, 12) . Therefore, the functional cytotoxic activity of both V β 17 ϩ and non-V β 17 ϩ M1 58-66 -specific clones was compared. In the presence of high concentrations of exogenous M1 58-66 peptide (10 -6 M), all clones produced similar levels of target cell lysis at equivalent E:T ratios (Fig. 1) . Similar levels of lysis were also seen at equivalent E:T ratios using targets infected with influenza A virus ( Fig. 1) confirming that clones expressing either the dominant V β 17 ϩ TCR or non-dominant TCR were able to recognize the M1 58-66 epitope after endogenous processing and presentation. Cytotoxicity was then compared using reducing concentrations of M1 58-66 peptide and a fixed E:T ratio of 5:1 for each clone. Three TCR V β 17 ϩ clones were compared with similar results (data not shown) and one selected for further study. Peptide sensitivity assays were performed in parallel on the V β 17 ϩ clone and the three clones expressing 'non-V β 17 ϩ ' TCR, using the same peptide-pulsed CIRA2 target cells. The TCR V β 17 ϩ clone lysed target cells at concentrations of M1 58-66 peptide Ͼ3 log 10 fold lower than the 'non-V β 17 ϩ ' clones ( Fig. 2) , suggesting that the V β 17 ϩ TCR have a greater affinity for HLA/A*0201/M1 58-66 than other M1 58-66 -specific TCR.
Binding of soluble HLA-A*0201/M1 58-66 tetramers
Given the reported relation between tetramer binding, TCR affinity and functional response observed following T cell activation (6,9,12,13), we assessed the binding of soluble HLA-A*0201/M1 58-66 tetramers to M1 58-66 -specific CTL clones, and compared this to the differences observed in the cytotoxicity assays. Equivalent tetramer binding to two V β 17 ϩ clones was confirmed in this study (data not shown), and similar binding of the same reagent to TCR V β 17 ϩ M1 58-66 -specific CTL lines and clones has been demonstrated in other studies (8, 14) . The TCR V β 17 ϩ and the TCR V β 8.1 ϩ clones bound tetramer with equal fluorescence intensity, but interestingly the V β 13.6 ϩ and the V β 23 ϩ clones did not bind tetramer, despite evidence of M1 58-66 -specific cytotoxicity (Fig. 3) . The concentration of tetramer used (0.5 mg/ml), produced saturation binding to V β 17 ϩ clones and the V β 8.1 ϩ clone, but even greater tetramer concentrations (1 mg/ml) did not result in any detectable binding to the V β 13.6 ϩ and the V β 23 ϩ clones (data not shown). The differences observed were independent of TCR expression; surface TCR αβ expression was least for the V β 17 ϩ clone and identical for the three 'non-V β 17 ϩ ' clones (Fig. 4) . The most likely explanation for the observed differences in tetramer binding was that it reflected variation in the affinity of the individual TCR for the HLA-A*0201/M1 58-66 complex.
Recently non-specific binding of tetramers through interaction with CD8 has been reported (15) . It was therefore important to exclude such an interaction for the V β 8.1 clone, the only 'non-V β 17' clone to bind tetramer. The V β 8.1 clone and, as a control, the V β 17 ϩ clone were stained with anti-CD8 (OKT8) to block CD8 binding sites prior to staining with tetramer. No significant decrease in tetramer binding to either clone was observed after CD8 staining (data not shown), suggesting that non-specific interaction with CD8 is unlikely to be the explanation for the observed differences in tetramer staining.
CD8 dependence
The importance of the CD8 co-receptor in the activation of CTL and the stabilization of the TCR-MHC-peptide interaction Cell-surface expression of TCRαβ was determined using TCR αβ-FITC followed by immunofluorescence analysis by FACS. This was performed on the same day as tetramer staining and determination of M1 58-66 -specific cytotoxicity and IFN-γ production. The V β 8.1 ϩ , V β 13.6 ϩ and V β 23 ϩ clones exhibited virtually identical levels of TCR αβ expression which were marginally greater than that of the V β 17 ϩ clone (shaded).
has been described in a number of studies (16) (17) (18) . CD8 is of particular importance when the interaction between the TCR and its MHC-peptide complex is of very low affinity and characterized by a rapid 'off-rate' (12, 18) . The CD8 dependence of the various M1 58-66 -specific CTL clones was compared by estimating the susceptibility of the clones to inhibition by anti-CD8 mAb (OKT8) to determine whether there . Lysis of targets in the absence of M1 58-66 peptide as Ͻ5%. E:T ratios of 5:1 were used for each clone. Assays were performed in triplicate wells and the mean percent specific lysis Ϯ SD is plotted. The V β 13.6 clone was not examined because of insufficient cell numbers.
was a difference between TCR V β 17 ϩ and 'non-V β 17 ϩ ' clones. These experiments were not performed on the TCR V β 13.6 ϩ clone because of insufficient cell numbers. Both the TCR V β 17 ϩ clone and the TCR V β 23 ϩ clone were CD8 independent, whereas the V β 8.1 ϩ clone was highly susceptible to inhibition by anti-CD8 mAb (Fig. 5) . Thus the clones could not be separated into TCR V β 17 ϩ and 'non-V β 17 ϩ ' groups based on their individual CD8 dependence. Furthermore, CD8 dependence did not correlate with TCR affinity inferred from peptide-dose response experiments (Fig. 2) .
Cell-surface phenotypes and cytokine production
Cytotoxicity is not the only effector function of CD8 ϩ T cells; IFN-γ and TNF-α release is also important (19) . In the presence of M1 58-66 peptide concentrations shown to produce maximal cytotoxic activity (10 -6 M), the M1 58-66 -specific clones expressing TCR incorporating the V β 17, V β 23 and V β 13.6 gene segments produced similar quantities of IFN-γ (Fig. 6A) . However, the V β 8.1 ϩ clone did not produce IFN-γ at peptide concentrations shown to produce maximal cytolytic activity (10 -6 M) (Fig. 6A) . The production of IFN-γ by antigen-specific CTL has previously been shown to require higher peptide concentrations than those required for cytotoxicity (20) . These findings were confirmed for the three clones that produced IFN-γ, by performing cytotoxicity assays and measuring IFN-γ production in parallel (Figs 2 and 6B) . Interestingly, however, the differences in peptide sensitivity between the V β 17 ϩ and 'non-V β 17 ϩ ' clones observed in cytotoxicity assays were not seen for IFN-γ release (Fig. 6B) . All IFN-γ-producing clones were able to produce TNF-α, but the V β 8.1 ϩ clone also failed to release this cytokine (data not shown). None of the clones released IL-1 or IL-4 (data not shown).
The V β 8.1 ϩ CTL clone was functionally distinct from the other clones in that it did not produce IFN-γ and was CD8 dependent. One possibility is that this CTL clone might belong to a CD8 T cell subset (21) . The expression levels of cellsurface markers CD11a, CD11b, CD27 and CD28 on the V β 8.1 ϩ clone were determined by flow cytometry and compared to those on V β 17 ϩ , V β 23 ϩ and V β 13.6 ϩ clones. The Fig. 7 . Overlay FACS histograms comparing CD11a, CD11b, CD27, CD28 and CD38 expression in the TCR V β 8 and TCR V β 13.6 clones. The TCR V β 8 clone (shaded area) showed increased surface expression of (C) CD27 (45%) and (D) CD28 (62%) compared to no expression in the other CTL clones, represented here by the TCR V β 13.6 clone (bold black line). There were no significant differences in (A) CD11a, (B) CD11b and (E) CD38 expression. Clones were stained with anti-CD8-TriColor, the appropriate anti-TCR V β -FITC and a range of phycoerythrin-conjugated mAb to the different cell-surface molecules. Analysis was carried out using standard lymphocyte gates on FSC/SSC, followed by gating on populations positive for CD8 and the appropriate TCR V β chain. V β 8.1 ϩ clone expressed high levels of CD11b, CD27 and CD28 (Fig. 7) . In contrast the V β 17 ϩ , V β 13.6 ϩ and V β 23 ϩ clones were C11b -, CD27 -and CD28 - (Fig. 7) .
Discussion
In this study we have compared the functional characteristics of dominant (V β 17 ϩ TCR) and subdominant CTL ('non-V β 17 ϩ 'TCR) clones recognizing the same HLA-A*0201/M1 58-66 complex. Generation of non-V β 17 ϩ CTL clones in vitro required the prior depletion of V β 17 ϩ T cells from PBMC, suggesting that V β 17 ϩ cells have a competitive advantage in vitro. In three donors it was not possible to generate non-V β 17 ϩ CTL clones unless dendritic cell-enriched stimulator cells were used for re-stimulation. This suggests either an extremely low frequency of non-V β 17 ϩ M1 specific CTL or that these CTL required additional co-stimulatory signals provided by dendritic cells.
We have shown that the TCR V β 17 ϩ clones require far lower concentrations of cognate peptide than the 'non-V β 17 ϩ ' clones to mediate cytotoxicity, although all CTL clones were able to lyse influenza A-infected target cells expressing endogenously processed antigen. This suggests that the V β 17 ϩ TCR have a greater affinity for the HLA-A*0201/M1 58-66 complex than non-V β 17 ϩ TCR (6, 12, 13, 22, 23) . This is supported by the observed binding of saturating concentrations of tetrameric complexes of HLA-A*0201/M1 58-66. All V β 17 ϩ clones bound this tetramer at high levels, while two out of three of the 'non-V β 17 ϩ ' clones were unable to bind tetramer despite clear evidence of peptide-specific cytotoxicity and IFN-γ production. Furthermore all tetramer staining was carried out at 4°C, under conditions shown to be optimal for detecting low-affinity cross-reactive TCR (24) . Since levels of TCR expression of V β 17 ϩ and 'non-V β 17 ϩ ' clones was equivalent, it is likely that the tetramer binding reflected the affinity of the TCR for the HLA-A*0201/M1 58-66 complex. However, the V β 8.1 ϩ clone which has a low affinity based on peptide titration (Fig. 2 ) was able to bind tetramer. This raises the possibility that tetramers, as currently configured are not the optimal structure for TCR recognition compared with the MHC class I-peptide complex on a target cell surface. Therefore, some caution must be exercised when assigning absolute TCR affinity and dissociation constants using these reagents.
However, this does not negate their value in relative and comparative studies (6) . The frequency of these non-tetramer binding CD8 ϩ CTL clones in the HLA-A*0201/M1 58-66 response and other antigen-specific responses remains unknown. The detection of such CTL among subdominant CTL suggests that the use of tetramer reagents in isolation may fail to detect a subset of antigen-specific T cells.
Anti-CD8 mAb have been used to block CTL-target interactions. These have been particularly effective in blocking responses of 'primary' CTL which have low avidity for target cells expressing the appropriate MHC-peptide complex. It is more difficult or impossible to block 'secondary' CTL derived by repeated antigen challenge in vivo or in vitro. In this study, two 'low-affinity' T cell clones as defined by peptide sensitivity and tetramer binding could not be blocked using anti-CD8 antibodies. This was also the case for V β 17 ϩ clones, so no correlation could be drawn between operationally defined TCR affinity and TCR dependence.
In this study, higher CTL avidity for HLA-A*0201/M1 58-66 correlated with expression of TCR V β 17. However, we did not observe any functional advantage of V β 17 ϩ clones in terms of IFN-γ production, as both V β 17 ϩ and 'non-V β 17 ϩ ' CTL (apart from the V β 8.1 ϩ clone) produced similar amounts of IFN-γ. This suggests that cytotoxicity may be the more important parameter for functional selection of CD8 ϩ T cells in this system.
The V β 8.1 ϩ CTL clone was remarkable in several respects. Firstly, despite having a lower affinity for the HLA-A*0201/ M1 58-66 complex as defined by peptide sensitivity, this clone was able to bind tetramer to the same level as V β 17 ϩ CTL clones. These results appear to be contradictory and do not necessarily imply that the V β 8.1 ϩ TCR has the same affinity for the HLA-A*0201/M1 58-66 complex as the V β 17 ϩ TCR as saturating doses of tetramer were used in this study. It is also possible that TCR with similar affinities for the same MHCpeptide ligand may differ with respect to their off-rate. This may be a more accurate indicator of the functional outcome following TCR activation by specific MHC-peptide ligand than TCR affinity (22, (25) (26) (27) . Determination of the kinetics of interaction of the V β 8.1 ϩ TCR with the HLA-A*0201/M1 58-66 complex might therefore explain the apparent discrepancy between tetramer binding and peptide sensitivity in cytotoxicity assays.
The V β 8.1 clone was the only clone whose cytotoxicity could be inhibited by anti-CD8 mAb, but was also the only 'non-V β 17 ϩ ' M1 58-66 -specific clone able to bind tetramer. Without detailed topological study of the interaction between the complete TCR αβ complex and the HLA-A*0201/M1 58-66 complex, it is difficult to explain this result. We confirmed that the tetramer staining of this clone was not through nonspecific interaction with CD8. In addition the V β 8.1 ϩ clone was the only CTL clone unable to produce detectable IFN-γ. The identification of a CD8 ϩ CTL clone which exhibits cytotoxicity, but fails to produce IFN-γ has implications for in vitro assays used in the ex vivo detection of CD8 ϩ CTL by the ELISPOT technique (7) . Although more sensitive than traditional cytotoxicity assays (7), in isolation it may fail to detect some antigen-specific cells. However, further studies are required to determine if this failure of IFN-γ release by the V β 8.1 ϩ clone is a consequence of long-term in vitro propagation.
The apparently contradictory results obtained with the V β 8.1 ϩ CTL illustrate the importance of studying TCR interactions with MHC-peptide complexes, free of other cellcell interactions. Most studies to date have examined the relationship between TCR affinity for MHC-peptide ligand and functional responses by introducing minor changes in the peptide (9, 12) . These studies have focused on a single TCR in each case. In this study we have identified four functionally heterogeneous clones with the same peptide specificity but different TCR. This provides an opportunity for comparative studies on the affinity and kinetics of TCR-MHC-peptide interaction against the same pathogen-derived MHC-peptide complex. It will therefore be important to compare the affinity and kinetics of interaction with the HLA-A*0201/M1 58-66 complex for these different TCR by surface plasmon resonance, thus removing the influence of other cell-cell interactions.
The respective in vivo roles of the dominant V β 17 ϩ CTL and subdominant 'non-V β 17 ϩ ' CTL in recovery from influenza infection is unknown. The selective expansion of CD8 ϩ CTL expressing TCR with the highest affinity for the HLA-A*0201/M1 58-66 complex may allow more rapid destruction of influenza-infected cells. If this is the case then why do subdominant 'non-V β 17 ϩ ' CTL persist in the peripheral blood? We have shown that these subdominant CTL can be expanded in vitro in the absence of the dominant V β 17 ϩ CTL. Such a phenomenon has been shown to occur in vivo for HLA-B8-restricted Epstein-Barr virus-specific CTL responses (28) . Studies in mouse strains with a deficiency of T cells bearing particular TCR V β genes have shown that peptide-specific T cell responses characterized by restricted TCR usage can be either crippled (29, 30) , reduced (31) (32) (33) or unaffected (34) . It remains to be determined whether this is dependent on the nature of the antigen or the experimental model used. Nevertheless, the persistence of subdominant CTL clones with heterogeneous TCR may provide a mechanism to cope with pathogen mutation.
In summary, we have demonstrated that although CTL expressing TCR incorporating the V β 17 gene segment dominate the HLA-A*0201-restricted influenza A/M1 58-66 -specific CTL response in man, a subdominant repertoire of CTL with heterogeneous V β gene segment usage exists, which can substitute for the dominant population in its absence in vitro. We identify an in vitro functional advantage of V β 17 ϩ clones over other clones in that they were able to mediate cytolysis at lower concentrations of peptide. We have also shown that two-thirds of the 'non-V β 17 ϩ ' clones generated failed to bind tetrameric HLA-A*0201/M1 58-66 molecules, thus identifying a potential limitation of these reagents particularly when used to study the antigen-selected TCR repertoire (35) . These studies also document the considerable functional heterogeneity of human CD8 ϩ CTL, even when specific for a single MHC-peptide complex and where oligoclonality of TCR usage is established. Thus, although the use of ELISPOT and tetramer assays have greatly increased the sensitivity of detection of CD8 ϩ CTL (36), it is clear that these techniques will still fail to detect some functional antigen-specific CD8 ϩ CTL in vitro.
